Editor's Pick:

During the 14th Five-Year Plan period (2021–25), China's medical and pharmaceutical sector has made significant progress in opening up. Key policies such as allowing wholly foreign-owned hospitals, expanding the use of gene and stem cell technologies, and relaxing entry for foreign investment in traditional Chinese medicine (TCM) have enabled foreign players to expand into the full industry chain — from healthcare services to R&D and high-end manufacturing.

Investments are concentrated in first-tier cities like Beijing, Shanghai, Guangzhou and free trade zones, with a focus on high-end medical devices, innovative drugs, and specialized healthcare services. With strong market demand and supportive policies, foreign enterprises in China are set for broader growth.